Exact Sciences Corporation (NASDAQ: EXAS) is carving a niche for itself in the healthcare sector with its innovative cancer screening and diagnostic products. With a market capitalization of $19.74 billion, this Madison, Wisconsin-based company is gaining traction among investors, thanks to its promising growth trajectory and strategic partnerships.
**Price and Valuation Metrics**
Exact Sciences’ stock is currently trading at $103.43, marking the upper limit of its 52-week range of $40.31 to $103.43. Despite this substantial rally, the company is not resting on its laurels. Analysts have set a target price range of $105.00 to $118.00, suggesting a potential upside of approximately 2.3%. The company’s forward P/E ratio stands…
